Experimence with mesterolone in male fertility disorders
Abstract
The use of mesterolone (30-75 mg daily for 60 days) in the treatment of primary and secondary male sterility (oligospermia, asthenospermia, a bnormal sperm viscosity, limited sperm survival time) in 141 patients is reported. Improvement of at least 1 symptom was seen in 44 patients. In 19 cases, the spouse became pregnant. The lower dose was associated with a somewhat higher improvement rate. Tolerance of mesterolone was excellent; side effects were observed in 2 patients. It is concluded that mesterolone is a useful addition to the therapeutic arsenal for the treatment of male infertility.
Read the paper
Related studies
- Evolution of testosterone treatment over 25 years: symptom responses, endocrine profiles and cardiovascular changes
- Vertebrate hormones influence on the reproduction of Biomphalaria glabrata and on Schistosoma mansoni infection (author's transl)
- Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation
- Successful treatment of methimazole-induced severe aplastic anaemia in a diabetic patient with other co-morbidities
- The management of male subfertility by in vitro fertilisation techniques
- Rapid determination of anti-estrogens by gas chromatography/mass spectrometry in urine: Method validation and application to real samples
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.